REGN - רווח לפני ריבית, מסים ופחת Regeneron

Regeneron Pharmaceuticals (REGN) is automating the creation of gene models via the VelociSuite AI system, reducing manual labor. Growth prospects are tied to the expanded application of Dupixent and successes in ophthalmology. This EBITDA chart reflects the real efficiency of the business, where the current level is around 5703.41. The company's competitive advantage is based on accelerated antibody synthesis and a stable cash flow from Eylea.

This indicator captures the actual daily cash volume, adjusted for accounting corrections and tax liabilities. The metric measures net operating cash flow before interest, excluding reporting manipulations. By analyzing the cash EBITDA trend, an investor sees the current value of 5703.41, which prevents overpaying for the asset. The stable cash flow of Regeneron Pharmaceuticals (REGN) from key drug sales confirms the resilience of this metric. Accumulated liquidity effectively mitigates the risks of patent expiration.